News - Neurological

Filter

Current filters:

Neurological

Popular Filters

101 to 125 of 912 results

Report: Alzheimer’s Disease market to reach $3.8 billion in 2019

Report: Alzheimer’s Disease market to reach $3.8 billion in 2019

27-12-2013

The Alzheimer’s Disease (AD) market will increase slightly from $3.6 billion in 2012 to $3.8 billion…

FinancialGlobalMarkets & MarketingNeurologicalPharmaceuticalResearch

Orion licenses Janssen to develop novel treatment for Alzheimer's disease

Orion licenses Janssen to develop novel treatment for Alzheimer's disease

20-12-2013

Orion Corp has entered into a license agreement with Janssen Pharmaceuticals for the development and…

FinlandJanssenLicensingNeurologicalNorthern EuropeOrion CorpPharmaceutical

Forest debuts MMD drug Fetzima in US pharmacies

19-12-2013

US drugmaker Forest Laboratories says that Fetzima (levomilnacipran ER capsules) is now available in…

FetzimaForest LaboratoriesMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPierre FabreUSA

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

19-12-2013

French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice…

BoardroomEuropeIpsenNeurologicalOncologyPharmaceutical

Targacept to drop development of TC-5619 in schizophrenia, after disappointing trial results

17-12-2013

Shares of US biopharma drug developer Targacept tanked nearly 33% to $4 in pre-market trading on December…

NeurologicalPharmaceuticalResearchTargaceptTC-5619

Patent expiries will push Parkinson’s drug market lower by 2019

17-12-2013

Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s disease (PD)…

GlobalImpax LaboratoriesMarkets & MarketingNeurologicalNewron PharmaPatentsPharmaceuticalpimavanserinRytarysafinamide

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

17-12-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive initial results from a Phase III study…

DysportIpsenNeurologicalNorthern EuropePharmaceuticalResearch

NuPathe rockets on news of takeover by Endo Health

NuPathe rockets on news of takeover by Endo Health

16-12-2013

In a third take-over deal announced this year, USA-based specialty health care company Endo Health Solutions…

Endo Health SolutionsMergers & AcquisitionsNeurologicalNuPathePharmaceuticalZecuity

Lundbeck appoints Jacob Tolstrup as senior vice president for Business Development

Lundbeck appoints Jacob Tolstrup as senior vice president for Business Development

16-12-2013

Danish pharmaceutical company H. Lundbeck A/S has appointed Jacob Tolstrup as head of the HR department…

BoardroomDenmarkEuropeH. LundbeckLundbeckNeurologicalPharmaceutical

Torrent to acquire Indian branded formulations from Elder

13-12-2013

Torrent Pharmaceuticals saw its shares rise 7% to 349 rupees after it said it is acquiring the branded…

Asia-PacificElder PharmaceuticalsIndiaMergers & AcquisitionsNeurologicalPharmaceuticalTorrent PharmaceuticalsWomen's Health

Retrophin to acquire Kyalin Biosciences; in-licenses Syntocinon

13-12-2013

In a second takeover bid within a matter of months, USA-based Retrophin announced that it will acquire…

Kyalin BiosciencesLicensingMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalRetrophinSyntocinonWomen's Health

Prothena inks deal with Roche, worth a potential $600 million

Prothena inks deal with Roche, worth a potential $600 million

12-12-2013

Biotech firm Prothena has entered into a worldwide collaboration with Swiss drug major Roche to develop…

BiotechnologyGlobalLicensingNeurologicalProthenaPRX002ResearchRoche

Lundbeck and Otsuka to co-develop Alzheimer’s vaccine, Lu AF20513

Lundbeck and Otsuka to co-develop Alzheimer’s vaccine, Lu AF20513

11-12-2013

Danish CNS specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical say they will further expand…

LicensingLu AF20513LundbeckNeurologicalOtsukaPharmaceuticalResearch

UK Dementia Consortium to bridge the gap between academia and pharma

UK Dementia Consortium to bridge the gap between academia and pharma

11-12-2013

The UK has today announced a new £3 million ($4.9 million) Dementia Consortium bringing together research…

EisaiEli LillyNeurologicalPharmaceuticalPoliticsResearchUK

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Teva provides 2014 financial outlook expecting big hit from Copaxone generics

Teva provides 2014 financial outlook expecting big hit from Copaxone generics

11-12-2013

Israel’s Teva Pharmaceutical Industries is itself bracing for competition from copies to its best-selling…

CopaxoneFinancialNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Lundbeck’s Brintellix scores well in new cognitive performance study

Lundbeck’s Brintellix scores well in new cognitive performance study

11-12-2013

Danish CNS specialist Lundbeck has released results from FOCUS, a new study showing that Brintellix (vortioxetine)…

BrintellixLundbeckNeurologicalPharmaceuticalResearch

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

10-12-2013

The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

Proteostasis Therapeutics in neurodegenerative disease deal with Biogen Idec

Proteostasis Therapeutics in neurodegenerative disease deal with Biogen Idec

10-12-2013

US drug developer Proteostasis Therapeutics has entered into a worldwide collaboration with biotech major…

Biogen IdecBiotechnologyLicensingNeurologicalProteostasis TherapeuticsResearch

Newron and Zambon file for EU approval of Parkinson’s drug safinamide

09-12-2013

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

EuropeNeurologicalNewron PharmaNorth AmericaPharmaceuticalRegulationsafinamideZambon

Sanofi’s Aubagio gains backing from UK’s NICE

Sanofi’s Aubagio gains backing from UK’s NICE

08-12-2013

In final draft guidance issued on Friday, the UK drugs watchdog the National Institute for Health and…

AubagioEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofiUK

Review of key drivers of migraine market growth through 2022

06-12-2013

Use of Allergan’s Botox (botulinum toxin type A) for the prophylactic treatment of chronic migraine…

AllerganAsia-PacificBotoxCoLucid PharmaceuticalsEuropelasmiditanLevadexMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Eli Lilly drops edivoxetine as adjunctive therapy for MDD

Eli Lilly drops edivoxetine as adjunctive therapy for MDD

06-12-2013

Given that results from three late-stage studies of edivoxetine did not meet the primary study objective…

edivoxetineEli LillyNeurologicalPharmaceutical

101 to 125 of 912 results

Back to top